Praxis Precision Medicines Inc. announced on July 17, 2025, that the U.S. Food and Drug Administration has granted breakthrough therapy designation (BTD) for their drug relutrigine. This designation is specifically for pediatric use in treating patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The BTD facilitates expedited development and review processes for drugs that aim to treat serious conditions, where preliminary clinical evidence suggests substantial improvement over existing therapies. The designation was supported by positive results from the Phase 2 EMBOLD study and 11-month data from its open-label extension. Additionally, Praxis has commenced the EMERALD study to further evaluate relutrigine across all DEEs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。